Home / Market News / $RVMD
benzinga Corporate Catalyst Impact 65/100 ● neutral

Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

Sep 28, 2026, 4:55 PM UTC · Primary ticker $RVMD

Brookline Capital initiated coverage on Revolution Medicines (RVMD) with a 'Buy' rating and a price target of $318. This analyst coverage and price target announcement could generate positive sentiment and increased investor interest in RVMD.

Brookline Capital's analyst Leah Rush initiated coverage on Revolution Medicines (RVMD) with a 'Buy' rating and a significant price target of $318. This event is a positive catalyst for RVMD as it signals a professional endorsement of the company's prospects and valuation. It primarily affects RVMD investors and potential investors, potentially leading to increased demand for the stock in the short term. The long-term implications depend on whether the company can meet the expectations set by this price target, but it provides a strong vote of confidence. For traders, this presents an opportunity for a potential upward movement in RVMD's stock price.

$RVMD positive Initiated with 'Buy' rating and high price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.